A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs

Cytometry Part B - Clinical Cytometry

Volumn 76, Issue 3, 2009, Pages 225-230

  Campioni, Diana ^a   Rizzo, Roberta ^b   Stignani, Marina ^b   Melchiorri, Loredana ^b   Ferrari, Luisa ^a   Moretti, Sabrina ^a   Russo, Antonio ^a   Bagnara, Gian Paolo ^c   Bonsi, Laura ^c   Alviano, Francesco ^c   Lanzoni, Giacomo ^c   Cuneo, Antonio ^a   Baricordi, Olavio R ^b,d   Lanza, Francesco ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b Section of Medical Genetics Department of Experimental and Diagnostic Medicine   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Biotechnology Center   (Italy)

Author keywords

CD90 antigen expression; In vitro T cell response; Mesenchymal stromal cells; Phenotypic markers on MSCs

Indexed keywords

HLA G ANTIGEN; INTERLEUKIN 10; THY 1 ANTIGEN;

ADULT; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION TEST; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYME CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STROMA CELL;

ADULT; ANTIGENS, THY-1; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED;

EID: 66949138068     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20461     Document Type: Article

References (19)

1. Le Blanc K, Tammik C, Rosendahl K. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal cells. Exp Hematol 2003;31:890-896.
2. Aggarwaal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2004;104:3410-3420.
3. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal cells suppress lymphocyte proliferation in vitro and prolonged skin graft survival in vivo. Exp Hematol 2002;30:42-48.
4. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of the severe autoimmune disease results from phase I/II study, prospective randomized trials and future directions. Clin Exp Immunol 2005;141:1-9.
5. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: A CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 2001;98:12150-12155.
6. Rizzo R, Campioni D, Stignani M, Melchiorri M, Bagnara GP, Bonsi L, Alviano F, Lanzoni G, Moretti S, Cuneo A, Lanza F, Baricordi OR. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 2008;10:364-375.
7. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F. HLA-G5 secretion by human mesenchymal stem cells is required to suppress T-lymphocyte and NK function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26:212-222.
8. Campioni D, Lanza F, Moretti S, Ferrari L, Cuneo A. Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from haematological patients may be induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy 2008;10:69-82.
9. Campioni D, Moretti S, Ferrari L, Castaldi GL, Lanza F. Immunóphenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: Correlation with bone marrow microenvironment. Haematologica 2006;91:364-368.
10. Rizzo R, Hviid TV, Stignani M. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics 2005;57:172-181.
11. Roederer M. Spectral compensation for flow cytometry: Visualization artefacts, limitations, and caveats. Cytometry 2001;45:194-205.
12. Rebmann V, Lemaoult J, Rouas-Freiss N. Report of the wet workshop for quantification of soluble HLA-G in Essen, 2004. Hum Immunol 2004;66:853-863.
13. Meisel R, Zibert A, Laryca M, Gobuel U, Aubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T- cell response by indoleamine 2,3-dioxigenase-mediated -tryptophan-degradation. Blood 2004;103:4619-4621.
14. Jones E, English A, Kinsey S, Emery P, Ponchel F, McGonagle D. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Cytometry Part B 2006;70B:391-399.
15. Soncini M, Vertua E, Gibelli L, Zorzi F, Denegri M, Albertini A, Wengler GS, Parolini O. Isolation and characterization of mesenchymal from human fetal membranes. J Tissue Eng Regen Med 2007;1:296-305.
16. Magatti M, De Munari S, Vertua E, Gibelli L, Wengler GS, Parolini O. Human Amnio mesenchyme harbors cells with allogenic T-cell suppression and stimulation capabilities. Stem Cells 2008;1:182-192.
17. Manca MF, Zwart I, Beo J, Palasingham R, Jen LS, Navarrete R, Girdlestone J, Navarrete CV. Characterization of mesenchymal stromal cells derived from full-term umbilical cord blood. Cytotherapy 2008;10:54-68.
18. Nadri S, Soleimani M. Comparative analysis of mesechymal stromal cells from mrine bone marrow and amniotic fluid. Cytotherapy 2007;9:729-737.
19. Horwitz EM. Mesenchymal stromal cells moving forward. Cytotherapy 2008;10:5-6.